Founded by pioneers in biopharmaceuticals with 50+ combined years of experience, Renova Therapeutics is developing a portfolio of definitive one-time gene therapy treatments as well as peptide infusion therapies to restore health to people suffering from cardiovascular and metabolic diseases.
Our Lead Product (RT-100)
A single dose of RT-100 – also known as AC6 gene transfer – has the potential to significantly improve heart function of CHF patients. Extensive preclinical research and Phase 2 trial results indicate that a one-time administration of RT-100 safely increases heart function beyond optimal heart failure therapy.
Our Paracrine Gene Therapy
Our proprietary paracrine gene therapy treatments are based on a novel systemic approach that introduces therapeutic genes capable of directing the body’s cells to work more normally. This single-IV injection approach is a foundation for products that may bring about substantial improvements in a variety of chronic cardiovascular and metabolic diseases.